Veraxa Biotech AG

Veraxa Biotech AG

NNASDAQ:VRXA
1.05
USD
-0.06
(-5.86%)
1.51BMarket Cap

Total Valuation

USD

As of December 31, 2025, Veraxa Biotech AG carries a market capitalization of 1.51B, placing it among publicly traded companies globally. Its enterprise value stands at 1.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.51B
Enterprise Value1.51B

Share Statistics

As of December 31, 2025, Veraxa Biotech AG has 141.41M shares outstanding.

Shares Outstanding141.41M

Valuation Ratios

These figures are as of December 31, 2025.

PB Ratio-75.83
P/TBV Ratio-13.21

Financial Position

As of December 31, 2025, Veraxa Biotech AG maintains a current ratio of 0.44, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities.

Current Ratio0.44
Quick Ratio0.42
Debt / Equity-13.58

Financial Efficiency

These figures cover the twelve months ended December 31, 2025.

Employee Count3.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Veraxa Biotech AG's stock has declined approximately 90.06% over the past 52 weeks. The 50-day moving average sits at 1.21, while the 200-day moving average is 6.44.

52-Week Price Change-90.06%
50-Day Moving Average1.21
200-Day Moving Average6.44

Balance Sheet

USD

As of December 31, 2025, Veraxa Biotech AG holds 2.04M in cash and equivalents against 2.70M in total debt, resulting in a net debt position of -774,866.86. Total book value stands at -19.90M, with working capital of -4.71M providing operational flexibility.

Cash & Cash Equivalents2.04M
Total Debt2.70M
Net Debt-774,866.86
Equity (Book Value)-19.90M
Book Value Per Share-0.14
Working Capital-4.71M